Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. ABBV
2. PRIM
3. DFTX
4. IBM
5. META
6. MU
7. DPZ
8. ACN
9. ZENA
10. CNC

Go back to Exelixis Announces Positive Results from Phase 2 CABOSUN Trial of Cabozantinib Versus Sunitinib in Previously Untreated Advanced Renal Cell Carcinoma Presented at ESMO 2016

Leerink Bumps PT on Exelixis (EXEL) Up to $16 Following Latest Cabozantinib Data

October 11, 2016 6:27 AM EDT

Leerink is boosting its price target on Outperform-rated Exelixis (Nasdaq: EXEL) from $15 to $16 after Exelixis announced detailed results from the CABOSUN randomized phase 2 trial of cabozantinib in patients with previously untreated advanced renal cell carcinoma (RCC) with intermediate- or poor-risk disease per the International Metastatic Renal Cell... More

Piper Jaffray Upgrades Exelixis (EXEL) to Overweight

October 10, 2016 9:09 AM EDT

Piper Jaffray upgraded Exelixis (NASDAQ: EXEL) from Neutral to Overweight.

For an analyst ratings summary and ratings history on Exelixis click here. For more ratings news on Exelixis click here.

Shares of Exelixis closed at $12.95 yesterday.

... More